Latest Clinical News

Trastuzumab emtansine Improves Treatment of Early Stage HER 2-positive Breast Cancer (12-12-2018)

Adjuvant trastuzumab emtansine showed improved disease-free survival compared with trastuzumab in HER2-positive early breast cancer. Patients with HER 2-positive early stage breast cancer with residual disease who received adjuvant trastuzumab emtansine... Continue Reading

Oxybutynin Decreased Frequency of Hot Flashes, Improved Quality of Life for Breast Cancer Survivors (12-11-2018)

Treatment with oxybutynin helped reduce the frequency and intensity of hot flashes for women who could not take hormone replacement, including breast cancer survivors, according to results of a trial presented at the 2018 San Antonio Breast Cancer Symposium,... Continue Reading

Choice of surgery may affect quality of life for young breast cancer survivors (12-10-2018)

Even as more young women with breast cancer opt to have mastectomies, many experience a persistent decline in their sexual and psychosocial well-being following the procedure, as detailed in new research by Dana-Farber/Brigham and Women’s Cancer Center.... Continue Reading

Gilteritinib Approved for Advanced Acute Myeloid Leukemia (AML) with a FLT3 Mutation (11-29-2018)

The U.S. Food and Drug Administration approved Xospata (gilteritinib) for treatment of adult patients who have recurrent or refractory acute myeloid leukemia (AML) with a FLT3 mutation. About Xospata Xospata has demonstrated inhibitory activity against... Continue Reading

Tissue “Agnostic” Genomic Based Treatment With Vitrakvi and Keytruda – A Paradigm Shift in Cancer Treatment (11-28-2018)

The US Food and Drug Administration (FDA) on Monday approved a new precision cancer medicine Vitrakvi (larotrectinib) for the treatment of adult and pediatric solid tumors that have a targetable biomarker known as a neurotrophic receptor tyrosine kinase... Continue Reading

FDA Approves Venclexta Combination for AML in Adults (11-26-2018)

The Food and Drug Administration granted accelerated approval to Venclexta (venetoclax) in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years... Continue Reading

Patients with rare, incurable digestive tract cancers respond to new drug combination (11-19-2018)

Dublin, Ireland: Patients with rare, but incurable cancers of the digestive tract have responded well to a combination of two drugs that block the MEK and BRAF pathways, which drive the disease in some cases. They have survived for longer without the... Continue Reading

Tivozanib for Renal Cell Cancer (11-16-2018)

The precision cancer medicine tivozanib delays cancer progression and prolongs survival in individuals with advanced renal cell cancer (RCC). About tivozanib Tivozanib is an oral vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor. In... Continue Reading

Keytruda Immunotherapy for Treatment of Liver Cancer (11-13-2018)

According to the results of a study presented at the recent gastrointestinal cancer symposia, Keytruda (pembrolizumab) is an active treatment for advanced liver cancer in patients who have already been treated with Nexavar (sorafenib), (1) and has not... Continue Reading

U.S. Food and Drug Administration Approves Empliciti® Plus Pomalidomide to Treat Certain Patients with Relapsed or Refractory Multiple Myeloma (11-12-2018)

The U.S. Food and Drug Administration (FDA) has approved Empliciti (elotuzumab) injection for intravenous use in combination with pomalidomide and dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who have received at least... Continue Reading

Lorbrena Approved for second- or third-line treatment of ALK-positive metastatic NSCLC (11-8-2018)

The US Food and Drug Administration granted accelerated approval to Lorbrena (lorlatinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on (Xalkori... Continue Reading

FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC (11-5-2018)

On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed... Continue Reading

Next Page »